{"id":206707,"date":"2023-01-23T05:44:12","date_gmt":"2023-01-23T05:44:12","guid":{"rendered":"https:\/\/www.healthbenefitstimes.com\/glossary\/?p=206707"},"modified":"2023-01-23T05:44:12","modified_gmt":"2023-01-23T05:44:12","slug":"multidrug-resistant-tuberculosis","status":"publish","type":"post","link":"https:\/\/www.healthbenefitstimes.com\/glossary\/multidrug-resistant-tuberculosis\/","title":{"rendered":"Multidrug resistant tuberculosis"},"content":{"rendered":"<p>Mycobacterium tuberculosis bacilli that are resistant to therapy with at least two standard antitubercular drugs (especially isoniazid and rifampin, the two drugs that have formed the cornerstone of therapy for tuberculosis). MDR-TB must be treated with at least three antitubercular drugs to which the organism is presumed or proven to be sensitive. About 3% of cases of TB are drug-resistant.<\/p>\n<hr \/>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mycobacterium tuberculosis bacilli that are resistant to therapy with at least two standard antitubercular drugs (especially isoniazid and rifampin, the two drugs that have formed the cornerstone of therapy for tuberculosis). MDR-TB must be treated with at least three antitubercular drugs to which the organism is presumed or proven to be sensitive. About 3% of [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["post-206707","post","type-post","status-publish","format-standard","hentry","category-m"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Multidrug resistant tuberculosis - Definition of Multidrug resistant tuberculosis<\/title>\n<meta name=\"description\" content=\"Mycobacterium tuberculosis bacilli that are resistant to therapy with at least two standard antitubercular drugs (especially isoniazid and rifampin, the two drugs that have formed the cornerstone of therapy for tuberculosis). MDR-TB must be treated with at least three antitubercular drugs to which the organism is presumed or proven to be sensitive. About 3% of cases of TB are drug-resistant.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.healthbenefitstimes.com\/glossary\/multidrug-resistant-tuberculosis\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Multidrug resistant tuberculosis - Definition of Multidrug resistant tuberculosis\" \/>\n<meta property=\"og:description\" content=\"Mycobacterium tuberculosis bacilli that are resistant to therapy with at least two standard antitubercular drugs (especially isoniazid and rifampin, the two drugs that have formed the cornerstone of therapy for tuberculosis). MDR-TB must be treated with at least three antitubercular drugs to which the organism is presumed or proven to be sensitive. About 3% of cases of TB are drug-resistant.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.healthbenefitstimes.com\/glossary\/multidrug-resistant-tuberculosis\/\" \/>\n<meta property=\"og:site_name\" content=\"Glossary\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-23T05:44:12+00:00\" \/>\n<meta name=\"author\" content=\"Glossary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Glossary\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/multidrug-resistant-tuberculosis\/\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/multidrug-resistant-tuberculosis\/\",\"name\":\"Multidrug resistant tuberculosis - Definition of Multidrug resistant tuberculosis\",\"isPartOf\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\"},\"datePublished\":\"2023-01-23T05:44:12+00:00\",\"dateModified\":\"2023-01-23T05:44:12+00:00\",\"author\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\"},\"description\":\"Mycobacterium tuberculosis bacilli that are resistant to therapy with at least two standard antitubercular drugs (especially isoniazid and rifampin, the two drugs that have formed the cornerstone of therapy for tuberculosis). MDR-TB must be treated with at least three antitubercular drugs to which the organism is presumed or proven to be sensitive. About 3% of cases of TB are drug-resistant.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/multidrug-resistant-tuberculosis\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.healthbenefitstimes.com\/glossary\/multidrug-resistant-tuberculosis\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/multidrug-resistant-tuberculosis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Multidrug resistant tuberculosis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\",\"name\":\"Glossary\",\"description\":\"Difinitions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\",\"name\":\"Glossary\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Multidrug resistant tuberculosis - Definition of Multidrug resistant tuberculosis","description":"Mycobacterium tuberculosis bacilli that are resistant to therapy with at least two standard antitubercular drugs (especially isoniazid and rifampin, the two drugs that have formed the cornerstone of therapy for tuberculosis). MDR-TB must be treated with at least three antitubercular drugs to which the organism is presumed or proven to be sensitive. About 3% of cases of TB are drug-resistant.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.healthbenefitstimes.com\/glossary\/multidrug-resistant-tuberculosis\/","og_locale":"en_US","og_type":"article","og_title":"Multidrug resistant tuberculosis - Definition of Multidrug resistant tuberculosis","og_description":"Mycobacterium tuberculosis bacilli that are resistant to therapy with at least two standard antitubercular drugs (especially isoniazid and rifampin, the two drugs that have formed the cornerstone of therapy for tuberculosis). MDR-TB must be treated with at least three antitubercular drugs to which the organism is presumed or proven to be sensitive. About 3% of cases of TB are drug-resistant.","og_url":"https:\/\/www.healthbenefitstimes.com\/glossary\/multidrug-resistant-tuberculosis\/","og_site_name":"Glossary","article_published_time":"2023-01-23T05:44:12+00:00","author":"Glossary","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Glossary","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/multidrug-resistant-tuberculosis\/","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/multidrug-resistant-tuberculosis\/","name":"Multidrug resistant tuberculosis - Definition of Multidrug resistant tuberculosis","isPartOf":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website"},"datePublished":"2023-01-23T05:44:12+00:00","dateModified":"2023-01-23T05:44:12+00:00","author":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5"},"description":"Mycobacterium tuberculosis bacilli that are resistant to therapy with at least two standard antitubercular drugs (especially isoniazid and rifampin, the two drugs that have formed the cornerstone of therapy for tuberculosis). MDR-TB must be treated with at least three antitubercular drugs to which the organism is presumed or proven to be sensitive. About 3% of cases of TB are drug-resistant.","breadcrumb":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/multidrug-resistant-tuberculosis\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.healthbenefitstimes.com\/glossary\/multidrug-resistant-tuberculosis\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/multidrug-resistant-tuberculosis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.healthbenefitstimes.com\/glossary\/"},{"@type":"ListItem","position":2,"name":"Multidrug resistant tuberculosis"}]},{"@type":"WebSite","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/","name":"Glossary","description":"Difinitions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5","name":"Glossary","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/"}]}},"_links":{"self":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/206707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/comments?post=206707"}],"version-history":[{"count":1,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/206707\/revisions"}],"predecessor-version":[{"id":206708,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/206707\/revisions\/206708"}],"wp:attachment":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/media?parent=206707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/categories?post=206707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/tags?post=206707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}